SXTP logo

60 DEGREES PHARMA INC

SXTPNASDAQ
๐Ÿ† #5161 by market capUS Equity
โ€”โ€”
Quote unavailable
๐Ÿ””
Track SXTP
Get earnings, price moves & breaking news on Telegram
Track
24hโ€”
7dโ€”
14dโ€”
30dโ€”
ytdโ€”
1yโ€”
๐ŸฆMarket Cap
$2M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
24.8%
Healthy
๐Ÿ“ŠGross Margin
26.3%
Moderate
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
1.7x
Cheap
Otter Score
โ€”
Insufficient data
No chart data available for SXTP.

Trading Snapshot

Day Range
โ€”
52-Week Range
$0.46 โ€“ $8.62
Volume (shares)
โ€”
Avg Volume (shares)
โ€”
Shares Outstanding
3.5M
Next Earnings
โ€”

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$207,898
P/E Ratio
โ€”
P/S Ratio
1.7x
EPS (TTM)
$-5.93
Dividend Yield
โ€”
SXTP logo

60 DEGREES PHARMA INC

SXTP
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About 60 DEGREES PHARMA INC

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.